Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report released on Friday,Benzinga reports. They currently have a $45.00 price target on the stock.

A number of other equities analysts have also recently issued reports on ORKA. Wedbush restated an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 price target on the stock. Finally, Wolfe Research assumed coverage on shares of Oruka Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $20.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Oruka Therapeutics has an average rating of “Buy” and a consensus target price of $39.86.

Oruka Therapeutics Price Performance

ORKA stock opened at $11.40 on Friday. Oruka Therapeutics has a 12 month low of $10.95 and a 12 month high of $53.88. The business’s 50-day moving average price is $17.74.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors have recently bought and sold shares of the business. AlphaCentric Advisors LLC purchased a new position in shares of Oruka Therapeutics in the 4th quarter valued at $119,000. China Universal Asset Management Co. Ltd. purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $144,000. Charles Schwab Investment Management Inc. bought a new position in Oruka Therapeutics in the fourth quarter worth about $303,000. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at about $343,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at about $1,037,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.